Alexa

Sanofi sees a return to growth starting in 2012

Sanofi sees a return to growth starting in 2012

Sanofi is promising a return to growth in the coming years following several dismal quarters that saw its profits hit hard by the expiration of the patents on some of its more expensive drugs.
The company said Tuesday that investment in research would help the company achieve an average annual sales growth of 5 percent between 2012 and 2015.
In addition, the last of a series of patents is set to expire next year. When patents expire, pharmaceutical companies face competition from cheaper generic versions of their drugs.
The company said sales growth and cost-cutting worth (EURO)2 billion ($2.8 billion) should see earnings per share grow slightly more than sales.


Updated : 2021-03-03 19:51 GMT+08:00